## Chloe J Jordan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3278097/publications.pdf

Version: 2024-02-01

		394421	361022
53	1,445 citations	19	35
papers	citations	h-index	g-index
			1.670
58	58	58	1679
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Sensitive periods of substance abuse: Early risk for the transition to dependence. Developmental Cognitive Neuroscience, 2017, 25, 29-44.	4.0	246
2	Progress in brain cannabinoid CB2 receptor research: From genes to behavior. Neuroscience and Biobehavioral Reviews, 2019, 98, 208-220.	6.1	139
3	Understanding Differences in Neurotypical and Autism Spectrum Special Interests Through Internet Forums. Intellectual and Developmental Disabilities, 2012, 50, 391-402.	1.1	68
4	Evolution of Autism Support and Understanding Via the World Wide Web. Intellectual and Developmental Disabilities, 2010, 48, 220-227.	1.1	66
5	Discovery and development of varenicline for smoking cessation. Expert Opinion on Drug Discovery, 2018, 13, 671-683.	5.0	65
6	Dissecting the Role of GABA Neurons in the VTA <i>versus</i> SNr in Opioid Reward. Journal of Neuroscience, 2020, 40, 8853-8869.	3.6	61
7	The highly selective dopamine D R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents. Neuropharmacology, 2019, 158, 107597.	4.1	51
8	Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine. Neuropharmacology, 2019, 158, 107609.	4.1	44
9	CB2 receptor antibody signal specificity: correlations with the use of partial CB2-knockout mice and anti-rat CB2 receptor antibodies. Acta Pharmacologica Sinica, 2019, 40, 398-409.	6.1	42
10	Systemizing and special interests: Characterizing the continuum from neurotypical to autism spectrum disorder. Learning and Individual Differences, 2014, 29, 98-105.	2.7	38
11	Perinatal Marijuana Use and the Developing Child. JAMA - Journal of the American Medical Association, 2018, 320, 545.	7.4	38
12	Adolescent Atomoxetine Treatment in a Rodent Model of ADHD: Effects on Cocaine Self-Administration and Dopamine Transporters in Frontostriatal Regions. Neuropsychopharmacology, 2013, 38, 2588-2597.	5.4	37
13	Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats. Acta Pharmacologica Sinica, 2019, 40, 365-373.	6.1	37
14	Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments. Drug and Alcohol Dependence, 2014, 140, 25-32.	3.2	36
15	New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders. Annual Review of Pharmacology and Toxicology, 2021, 61, 609-628.	9.4	36
16	Translating the atypical dopamine uptake inhibitor hypothesis toward therapeutics for treatment of psychostimulant use disorders. Neuropsychopharmacology, 2019, 44, 1435-1444.	5.4	35
17	mCluR5 antagonism inhibits cocaine reinforcement and relapse by elevation of extracellular glutamate in the nucleus accumbens via a CB1 receptor mechanism. Scientific Reports, 2018, 8, 3686.	3.3	32
18	Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: Methylphenidate vs. atomoxetine treatments. Behavioural Brain Research, 2013, 244, 38-47.	2.2	31

#	Article	IF	Citations
19	Dopamine, behavior, and addiction. Journal of Biomedical Science, 2021, 28, 83.	7.0	25
20	Newly Developed Dopamine D <sub>3</sub> Receptor Antagonists, <i>R</i> -VK4-40 and <i>R</i> -VK4-116, Do Not Potentiate Cardiovascular Effects of Cocaine or Oxycodone in Rats. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 602-614.	2.5	24
21	Adolescent d-amphetamine treatment in a rodent model of ADHD: Pro-cognitive effects in adolescence without an impact on cocaine cue reactivity in adulthood. Behavioural Brain Research, 2016, 297, 165-179.	2.2	20
22	Genetic deletion of the dopamine D3 receptor increases vulnerability to heroin in mice. Neuropharmacology, 2018, 141, 11-20.	4.1	20
23	Performance on a strategy set shifting task in rats following adult or adolescent cocaine exposure. Psychopharmacology, 2014, 231, 4489-4501.	3.1	19
24	Optogenetic brainâ€stimulation reward: A new procedure to reâ€evaluate the rewarding <i>versus</i> aversive effects of cannabinoids in dopamine transporterâ€Cre mice. Addiction Biology, 2021, 26, e13005.	2.6	19
25	Deletion of the type 2 metabotropic glutamate receptor increases heroin abuse vulnerability in transgenic rats. Neuropsychopharmacology, 2018, 43, 2615-2626.	5.4	18
26	Adolescent d-amphetamine treatment in a rodent model of attention deficit/hyperactivity disorder: impact on cocaine abuse vulnerability in adulthood. Psychopharmacology, 2016, 233, 3891-3903.	3.1	16
27	Introduction to the Special Issue on "Informing Longitudinal Studies on the Effects of Maternal Stress and Substance Use on Child Development: Planning for the HEALthy Brain and Child Development (HBCD) Study― Adversity and Resilience Science, 2020, 1, 217-221.	2.6	16
28	(±)VK4â€40, a novel dopamine D <sub>3</sub> receptor partial agonist, attenuates cocaine reward and relapse in rodents. British Journal of Pharmacology, 2020, 177, 4796-4807.	5.4	15
29	Definitions of neonatal abstinence syndrome in clinical studies of mothers and infants: an expert literature review. Journal of Perinatology, 2021, 41, 1364-1371.	2.0	14
30	Neural regulation of the time course for cocaineâ€cue extinction consolidation in rats. European Journal of Neuroscience, 2013, 37, 269-277.	2.6	13
31	Juvenile exposure to methylphenidate and guanfacine in rats: effects on early delay discounting and later cocaine-taking behavior. Psychopharmacology, 2019, 236, 685-698.	3.1	13
32	Xie2-64, a novel CB2 receptor inverse agonist, reduces cocaine abuse-related behaviors in rodents. Neuropharmacology, 2020, 176, 108241.	4.1	13
33	Modafinil potentiates cocaine self-administration by a dopamine-independent mechanism: possible involvement of gap junctions. Neuropsychopharmacology, 2020, 45, 1518-1526.	5.4	13
34	Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence–based approach. Part II: The clinical application of nonpharmacologic care for NAS/NOWS. Neurotoxicology and Teratology, 2021, 88, 107032.	2.4	12
35	Working memory and salivary brainâ€derived neurotrophic factor as developmental predictors of cocaine seeking in male and female rats. Addiction Biology, 2018, 23, 868-879.	2.6	11
36	Involvement of the ghrelin system in the maintenance of oxycodone self-administration: converging evidence from endocrine, pharmacologic and transgenic approaches. Molecular Psychiatry, 2022, 27, 2171-2181.	7.9	9

#	Article	IF	CITATIONS
37	Neuropsychopharmacology (NPP): gender balance in journal function. Neuropsychopharmacology, 2019, 44, 4-8.	5.4	8
38	Virtual meetings: A critical step to address climate change. Science Advances, 2020, 6, .	10.3	8
39	Effects of the COVID-19 pandemic on gender representation among corresponding authors of Neuropsychopharmacology (NPP) manuscripts: submissions during January–June, 2020. Neuropsychopharmacology, 2021, 46, 269-270.	5.4	7
40	Identification of the Risk Genes Associated With Vulnerability to Addiction: Major Findings From Transgenic Animals. Frontiers in Neuroscience, 2021, 15, 811192.	2.8	6
41	Neuropsychopharmacology (NPP): relationships between online attention and citation counts. Neuropsychopharmacology, 2019, 44, 1513-1515.	5.4	5
42	Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach. Neurotoxicology and Teratology, 2021, 88, 107020.	2.4	5
43	NPP (Neuropsychopharmacology): update on gender balance in journal function. Neuropsychopharmacology, 2019, 44, 2145-2148.	5.4	4
44	Synaptic Zn2+ potentiates the effects of cocaine on striatal dopamine neurotransmission and behavior. Translational Psychiatry, 2021, 11, 570.	4.8	3
45	Neuropsychopharmacology (NPP) 2020 report on gender balance among corresponding authors and reviewers: before and during the COVID-19 pandemic. Neuropsychopharmacology, 2022, 47, 973-975.	5.4	3
46	Cannabis Use Disorder During the Perinatal Period. , 2019, , 177-188.		2
47	Neuropsychopharmacology (NPP): update on relationships between online attention and citation counts. Neuropsychopharmacology, 2021, 46, 1061-1063.	5.4	1
48	C.10 - METHYLPHENIDATE AND ATOMOXETINE TREATMENT IN THE SPONTANEOUSLY HYPERTENSIVE RAT MODEL OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER. Behavioural Pharmacology, 2013, 24, e33.	1.7	0
49	Attention Deficit Hyperactivity Disorder (ADHD): Methylphenidate (Ritalin) andÂDopamineâ~†., 2017, , .		0
50	ACNP efforts toward reducing climate change. Neuropsychopharmacology, 2020, 45, 2137-2138.	5.4	0
51	Pharmacology in the age of circuit neuroscience: Illuminating the neural mechanisms of reward, drug use and addiction and enlightening the future of translational research. Pharmacology Biochemistry and Behavior, 2021, 206, 173187.	2.9	0
52	Gap Junctions Modulate The Effects Of Modafinil On Cocaine Selfâ€Administration Behavior In A Dopamineâ€Independent Fashion In Rats. FASEB Journal, 2020, 34, 1-1.	0.5	0
53	Perinatal Substance Use Disorders: Intrauterine Exposure. , 2021, , 1529-1547.		0